Loading stock data…
$6.56-0.50 (-7.08%)
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
Alumis Inc. in the Healthcare sector is trading at $6.56 with a market capitalization of $885M. Wall Street consensus targets $31.12 (8 analysts), implying a +374.5% move over the next 12 months. The stock is currently near its 52-week low of $4.37, remaining 70.2% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.66M↓ | $1.74M↓ | $1.93M↓ | $2.07M↓ | $2.67M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$107.03M↓ | -$98.41M↓ | -$96.44M↑ | -$115.29M↑ | -$140.54M |
| Net Income | -$142.22M↓ | -$93.05M↓ | -$92.93M↑ | -$110.75M↓ | $59.32M |
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psori...